ERS International Congress, Milan 2017

---

Airway disease and exacerbations

Thematic Poster
Chairs: J. García Rivero (Mogro (Cantabria), Spain), P. Burgel (Paris, France), J. Chorostowska-Wynimko (Warszawa, Poland)

Suitability of patients with perceived AECOPD for referral to a COPD unit at a district general hospital A. Macfoy (Manchester, United Kingdom)
Peripheral blood eosinophil counts in COPD patients and its relationship with prescription of inhaled corticosteroid in real world setting in Japan. H. Nagase (Tokyo, Japan)
Acinar and bronchial nitric oxide levels in stable and exacerbated COPD. Z. Lázár (Budapest, Hungary)
COPD non-exacerbator phenotype is associated with current smoking but not with Haptoglobin phenotype M. Shteinberg (Haifa, Israel)
Comorbidity related hospitalizations among COPD patients indicated for long-term oxygen therapy N. Kyuchukov (Pleven, Bulgaria)
Stability of fixed airflow limitation in patients with asthma: 1 year follow-up G. Sergeeva (St Petersburg, Russian Federation)
Psychological factors influencing results of Asthma Control Test (ACT) M. Przybyszowski (Kraków, Poland)
Local and systemic nucleic acid damage in COPD exacerbations. I. Barta (Budapest, Hungary)
Asthma Control Test (ACT) result as a predictor of asthma exacerbations M. Przybyszowski (Kraków, Poland)
Evaluation of asthma control from China national asthma control surveys J. Lin (BEIJING, China)
Does a composite score combining peripheral blood eosinophils (PBE) and exhaled nitric oxide (FeNO) accurately predict a sputum eosinophilia? K. Borg (Oxford, United Kingdom)
Breath sound analysis could predict the length of symptomatic days of wheezy children K. Iikura (Tokyo, Japan)
Clinical utility of measuring FeNO to assess inhaled corticosteroid response in asthma. B. Krishnan (Trivandrum (Kerala), India)
Baseline serum CCL5 as a predictor for loss of asthma control and exacerbation during step-wise treatment reduction. N. Mohd Aminudin (shah alam, Malaysia)
Comparison of clinical features and outcome in COPD patients with and without heart failure, admitted at tertiary care hospital. S. Ashraf (Peshawar, Pakistan)
Point of care measurement of eosinophil derived neurotoxin (EDN) as a biomarker of eosinophilic asthma S. Young (Melbourn, United Kingdom)
Red blood cell distribution width in patients with chronic obstructive lung disease:how is changed in exacerbation? S. Alparslan Bekir (ISTANBUL, Turkey)
Markers of severity and inflammatory profile during exacerbations of severe asthma. U. Hoda (St Albans, United Kingdom)
Imbalance of anti-inflammatory (resolving D1) and pro-inflammatory (leukotrien B4) arachidonic acid products in exhaled breath condensate of severe refractory asthma. V. Sedlák (Hradec Králové 9, Czech Republic)
Clinical characteristics and prognostic features in infectious and non-infectious COPD exacerbations S. Atis Nayci (Mersin, Turkey)